These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. Caputo E; Miceli R; Motti ML; Taté R; Fratangelo F; Botti G; Mozzillo N; Carriero MV; Cavalcanti E; Palmieri G; Ciliberto G; Pirozzi G; Ascierto PA J Transl Med; 2014 Jul; 12():216. PubMed ID: 25074438 [TBL] [Abstract][Full Text] [Related]
67. [CD160 characterization and its association with disease progression in patients with chronic HIV-1 infection]. Wang L; Xu X; Feng G; Zhang X; Wang F Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1559-62. PubMed ID: 25146744 [TBL] [Abstract][Full Text] [Related]
68. Expansion of CD4 phenotype among CD160 receptor-expressing lymphocytes in murine pregnancy. Meggyes M; Szereday L; Jakso P; Bogar B; Bogdan A; Nörenberg J; Miko E; Barakonyi A Am J Reprod Immunol; 2017 Dec; 78(6):. PubMed ID: 28921767 [TBL] [Abstract][Full Text] [Related]
69. Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation. Maeda M; Carpenito C; Russell RC; Dasanjh J; Veinotte LL; Ohta H; Yamamura T; Tan R; Takei F J Immunol; 2005 Oct; 175(7):4426-32. PubMed ID: 16177084 [TBL] [Abstract][Full Text] [Related]
70. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780 [TBL] [Abstract][Full Text] [Related]
71. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes. Horn LA; Long TM; Atkinson R; Clements V; Ostrand-Rosenberg S Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838 [TBL] [Abstract][Full Text] [Related]
73. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in White MG; Szczepaniak Sloane R; Witt RG; Reuben A; Gaudreau PO; Andrews MC; Feng N; Johnson S; Class CA; Bristow C; Wani K; Hudgens C; Nezi L; Manzo T; De Macedo MP; Hu J; Davis R; Jiang H; Prieto P; Burton E; Hwu P; Tawbi H; Gershenwald J; Lazar AJ; Tetzlaff MT; Overwijk W; Woodman SE; Cooper ZA; Marszalek JR; Davies MA; Heffernan TP; Wargo JA Oncoimmunology; 2021; 10(1):1992880. PubMed ID: 34777916 [TBL] [Abstract][Full Text] [Related]
74. Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis. An Q; Liu Z BMC Cancer; 2019 Jan; 19(1):43. PubMed ID: 30626368 [TBL] [Abstract][Full Text] [Related]
75. Targeting oncogenic drivers and the immune system in melanoma. McArthur GA; Ribas A J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252 [TBL] [Abstract][Full Text] [Related]
76. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Cai G; Freeman GJ Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226 [TBL] [Abstract][Full Text] [Related]
77. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Fourcade J; Sun Z; Pagliano O; Guillaume P; Luescher IF; Sander C; Kirkwood JM; Olive D; Kuchroo V; Zarour HM Cancer Res; 2012 Feb; 72(4):887-96. PubMed ID: 22205715 [TBL] [Abstract][Full Text] [Related]
78. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Boni A; Cogdill AP; Dang P; Udayakumar D; Njauw CN; Sloss CM; Ferrone CR; Flaherty KT; Lawrence DP; Fisher DE; Tsao H; Wargo JA Cancer Res; 2010 Jul; 70(13):5213-9. PubMed ID: 20551059 [TBL] [Abstract][Full Text] [Related]
79. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Sottile R; Pangigadde PN; Tan T; Anichini A; Sabbatino F; Trecroci F; Favoino E; Orgiano L; Roberts J; Ferrone S; Kärre K; Colucci F; Carbone E Eur J Immunol; 2016 Feb; 46(2):409-19. PubMed ID: 26564811 [TBL] [Abstract][Full Text] [Related]